Please ensure Javascript is enabled for purposes of website accessibility

Why Vericel Tumbled by Nearly 15% on Tuesday

By Eric Volkman - Jun 29, 2021 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA says "no" to the company's NexoBrid -- for now.

What happened

Tuesday was not a good day to be a Vericel (VCEL -8.08%) investor. Discouraging news from a top regulator put investors in sell-off mode, with the stock falling by 14.8% on the day.

So what

In what must have been a painful admission, Vericel announced Tuesday morning that the biotech's development partner MediWound received what amounts to a rejection letter from the FDA. Formally speaking, this was a complete response letter from the regulator, in which it said it could not approve the biologics license application (BLA) for the two companies' NexoBrid in the BLA's current form.

Doctor treating a patient's hand injury.

Image source: Getty Images.

Vericel claimed the FDA's rejection was based on several different factors. These include difficulties with the chemistry, manufacturing, and controls section of the BLA (for which the regulator has requested more information), and a requirement that production facilities be inspected.

Despite the setback, Vericel said, "We are committed to working with MediWound and the FDA on next steps to address the issues identified in the complete response letter in order to obtain the potential approval of NexoBrid and bring this important product to patients as expeditiously as possible."

Now what

NexoBrid can indeed be an important product, as it's a therapy that treats the damage from severe burns. Since it has tested very well in late-stage clinical trials, this setback is more due to procedure than the product's efficacy. We can expect Vericel and MediWound to correct the BLA's issues, and hopefully by doing so obtain the regulatory approval they seek.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vericel Corporation Stock Quote
Vericel Corporation
$27.43 (-8.08%) $-2.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.